Hôpital Beaujon

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures	Carcinoma, Ductal, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, microphthalmia, syndromic 9, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm	Active, not recruiting	Not applicable	2026-10-01		NCT05475366
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	Recruiting	Phase 1 / Phase 2	2026-05-11		NCT06501625

Clinical trials